In a finding that could alter treatment for heart patients, those who took the anticlotting drug rivaroxaban daily after a heart attack or life-threatening chest pain had a lower risk of dying or suffering another heart attack than patients who took a placebo, according to researchers. C. Michael Gibson, HMS associate professor of medicine at Beth Israel Deaconess Medical Center and Jessica Mega, HMS assistant professor of medicine at Brigham and Women’s Hospital, are study co-authors.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?